Severe Asthma Clinical Trial
Official title:
Escitalopram in the Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
The purpose is to determine if: 1) Escitalopram treatment will be associated with less oral corticosteroid use than placebo in outpatients with severe asthma and moderate or severe major depressive disorder (MDD). 2) Escitalopram treatment will be associated with greater improvement in asthma symptoms than placebo in outpatients with severe asthma and moderate or severe MDD. 3) Escitalopram treatment will be associated with greater depressive symptom remission rates than placebo in outpatients with severe asthma and moderate or severe MDD.
Status | Completed |
Enrollment | 26 |
Est. completion date | March 2010 |
Est. primary completion date | March 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Current HAM-D score of = 20 - Patients with severe asthma (defined as asthma requiring three or more course of oral corticosteroids in the past year). - No changes in asthma medications, oral corticosteroid use, or treatment for respiratory tract infections in the past week - Needs to have taken = 3 courses of oral corticosteroids, for asthma, in the past 12 months. - Both male and female - English- or Spanish-speaking Exclusion Criteria: - Current substance or alcohol abuse/dependence - MDD with psychotic features (delusions, hallucinations, disorganized thought processes) - Bipolar disorder - Schizophrenia or schizoaffective disorder - Substance-induced mood disorder and mood disorder secondary to a general medical condition - Mental retardation or other severe cognitive impairment - Prison or jail inmates - Pregnant or nursing women or women of childbearing age who will not use The University of Texas Southwestern Medical Center - Institutional Review Board (UTSW IRB) approved methods of birth control or abstinence during the study - Treatment-resistant depressed persons defined as having failed two adequate trials of antidepressants - Current antipsychotic or antidepressant therapy or psychotherapy - Initiation of other psychotropic medications or psychotherapy within past 2 weeks (e.g., anxiolytics, hypnotics) |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | The UT Southwestern Medical Center at Dallas | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center | Forest Laboratories |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | HAM-D (Hamilton Rating Scale for Depression) | The HAM-D is a 17 item questionnaire (a clinician-administered depression scale) designed to evaluate severity of depressive symptoms. Scores can range from 0 to 52. The higher the score, the worse the depressive symptoms (worse outcome). | Baseline | No |
Primary | ACQ (Asthma Control Questionnaire) | The ACQ is a questionnaire used to assess symptoms pertinent to asthma management. Scores range from 0 to 42. The higher the score, the worse the asthma symptoms (worse outcome). The total ACQ score is obtained by dividing the raw score by the total number of items (in this case 7 items). | Baseline | No |
Primary | IDS-SR (Inventory of Depressive Symptomatology - Self-Report) | The IDS-SR is a 30 item (self-report questionnaire) designed to assess symptoms of depression. Scores range from 0 to 90. The higher the score, the worse the depressive symptoms (worse outcome). | Baseline | No |
Primary | HAM-D (Hamilton Rating Scale for Depression) | The HAM-D is a 17 item questionnaire (a clinician-administered depression scale) designed to evaluate severity of depressive symptoms. Scores can range from 0 to 52. The higher the score, the worse the depressive symptoms (worse outcome). | Up to 12 weeks | No |
Primary | ACQ (Asthma Control Questionnaire) | The ACQ is a questionnaire used to assess symptoms pertinent to asthma management.Scores range from 0 to 42. The higher the score, the worse the asthma symptoms (worse outcome). The total ACQ score is obtained by dividing the raw score by the total number of items (in this case 7 items). | Up to 12 weeks | No |
Primary | IDS-SR (Inventory of Depressive Symptomatology - Self-Report) | The IDS-SR is a 30 item (self-report questionnaire) designed to assess symptoms of depression. Scores range from 0 to 90. The higher the score, the worse the depressive symptoms (worse outcome). | Up to 12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05018299 -
Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma
|
Phase 2 | |
Recruiting |
NCT05472324 -
Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.
|
Phase 2 | |
Recruiting |
NCT04914078 -
Severe Asthma Exacerbations and Mepolizumab Treatment
|
||
Completed |
NCT05576454 -
Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects
|
Phase 1 | |
Recruiting |
NCT04520165 -
Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
|
||
Recruiting |
NCT04438408 -
National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
|
||
Not yet recruiting |
NCT04463836 -
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
|
||
Recruiting |
NCT03377920 -
Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.
|
N/A | |
Recruiting |
NCT04565483 -
Predictive Signature of Benralizumab Response
|
Phase 4 | |
Recruiting |
NCT04045587 -
International Severe Asthma Registry: Canadian Cohort
|
||
Completed |
NCT05616338 -
Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)
|
N/A | |
Active, not recruiting |
NCT02038374 -
Clinico-biological Correlation of Severe Asthma in Children
|
N/A | |
Active, not recruiting |
NCT02114034 -
Cohort Analysis of Clinical and Biological Severe Childhood Asthma
|
||
Recruiting |
NCT06035289 -
Register Schweres Asthma - German Asthma Net e.V.
|
||
Not yet recruiting |
NCT03532685 -
Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up
|
N/A | |
Completed |
NCT03931954 -
Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
|
||
Recruiting |
NCT03984253 -
Swiss Severe Asthma Register
|
||
Recruiting |
NCT03435237 -
Phenotyping Asthma for Bronchial Thermoplasty
|
||
Recruiting |
NCT03476109 -
Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.
|
Phase 4 | |
Active, not recruiting |
NCT06389058 -
Using NLP and Neural Networks to Autonomously Identify Severe Asthma and Determine Study Eligibility in a Large Healthcare System
|